↓ Skip to main content

Cannabinoids Inhibit T-cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction

Overview of attention for article published in Journal of NeuroImmune Pharmacology, July 2013
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#12 of 435)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
35 tweeters
facebook
21 Facebook pages
googleplus
1 Google+ user

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
27 Mendeley
Title
Cannabinoids Inhibit T-cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction
Published in
Journal of NeuroImmune Pharmacology, July 2013
DOI 10.1007/s11481-013-9485-1
Pubmed ID
Authors

Rebecca Hartzell Robinson, Joseph J. Meissler, Jessica M. Breslow-Deckman, John Gaughan, Martin W. Adler, Toby K. Eisenstein

Abstract

Cannabinoids are known to have anti-inflammatory and immunomodulatory properties. Cannabinoid receptor 2 (CB2) is expressed mainly on leukocytes and is the receptor implicated in mediating many of the effects of cannabinoids on immune processes. This study tested the capacity of Δ(9)-tetrahydrocannabinol (Δ(9)-THC) and of two CB2-selective agonists to inhibit the murine Mixed Lymphocyte Reaction (MLR), an in vitro correlate of graft rejection following skin and organ transplantation. Both CB2-selective agonists and Δ(9)-THC significantly suppressed the MLR in a dose dependent fashion. The inhibition was via CB2, as suppression could be blocked by pretreatment with a CB2-selective antagonist, but not by a CB1 antagonist, and none of the compounds suppressed the MLR when splenocytes from CB2 deficient mice were used. The CB2 agonists were shown to act directly on T-cells, as exposure of CD3(+) cells to these compounds completely inhibited their action in a reconstituted MLR. Further, the CB2-selective agonists completely inhibited proliferation of purified T-cells activated by anti-CD3 and anti-CD28 antibodies. T-cell function was decreased by the CB2 agonists, as an ELISA of MLR culture supernatants revealed IL-2 release was significantly decreased in the cannabinoid treated cells. Together, these data support the potential of this class of compounds as useful therapies to prolong graft survival in transplant patients.

Twitter Demographics

The data shown below were collected from the profiles of 35 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 22%
Student > Bachelor 5 19%
Student > Ph. D. Student 4 15%
Unspecified 3 11%
Other 3 11%
Other 6 22%
Readers by discipline Count As %
Medicine and Dentistry 7 26%
Agricultural and Biological Sciences 5 19%
Unspecified 3 11%
Chemistry 3 11%
Immunology and Microbiology 3 11%
Other 6 22%

Attention Score in Context

This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2018.
All research outputs
#429,094
of 12,861,409 outputs
Outputs from Journal of NeuroImmune Pharmacology
#12
of 435 outputs
Outputs of similar age
#5,986
of 151,527 outputs
Outputs of similar age from Journal of NeuroImmune Pharmacology
#3
of 15 outputs
Altmetric has tracked 12,861,409 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 435 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 151,527 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.